News ASCO26: DNA test could spare breast cancer patients chemo Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.
Patients ASCO 26: War, disasters, policy compound cancer care challen... A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.
Oncology ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.
News ASCO26: Big win for Erleada in perioperative prostate cancer ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.
News ASCO26: Revolution's 'grand slam' data in pancreatic cancer Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
News ASCO26: Lilly's Retevmo aces early-stage lung cancer trial Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.